Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4618 The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumours

Introduction: Colonic neuroendocrine tumours (NETs), excluding rectal NETs, are often described as relatively common and aggressive, with inferior median survival compared to other gastrointestinal (GI) primary sites. However, epidemiological databases may conflate well-differentiated NETs with poorly differentiated NECs, leading to unclear data on prevalence, clinical behaviour, and prognosis of well-differentiated colonic NETs.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Strosberg J,

Keywords: colon, neuroendocrine tumour, caecum, sigmoid, neuroendocrine neoplasm,

#4589 Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),

#4031 68-Gallium DOTANOC PET/CT pitfall in adnexal tumor

Introduction: PET/CT with 68Ga-DOTA is a commonly used tool in the baseline evaluation and follow-up of NETs due to its high specificity and sensitivity, showing better performance than CT in detecting primary and metastatic disease. However, we must know more about its normal physiological distribution, its variation in pathologies, and the possibility of confusion with benign processes to optimize its interpretation.

Conference:

Presenting Author:

Authors: González Devia D, Chaar-Lugo A, Rojas-Camacho J, Londoño-Schimmer E, Buriticá-Cifuentes C,

Keywords: Neuroendocrine tumor, 68Ga-DOTANOC, PET/CT, Rectal neuroendocrine tumor, Adnexal tumor, Pitfalls,

#3986 The application of 68Ga-DOTANOC PET/CT after endoscopic submucosal dissection for patients with rectal NET

Introduction: Some rectal neuroendocrine tumors (NETs) are accidentally detected by colonoscopy screening. Due to the lack of cognition of endoscopic feature of rectal NET, endoscopic tumor resection has always done without metastasis screening.

Conference:

Presenting Author: Xu J

Authors: Bian J, Xu X, Liang Y, Huang J, Chen S,

Keywords: rectal neuroendocrine tumor, 68Ga-DOTANOC, PET/CT, endoscopic submucosal dissection,